Related Insights
EU Pharmaceutical Production Down Nearly 6% in Germany: Supply Chain Implications
Chemeurope confirmed that German chemical and pharmaceutical production fell by 2.8% in Q1 2026
Pharmaceutical Packaging Polymers: The Duty-Waiver Aftermath and Indian Medical Device Competitiveness
India's medical device polymer packaging inputs (PP for syringes, PVC for IV bags, PC for connectors
Houston Ship Channel Reopens: What It Means for Construction Chemical Supply in H2 2026
The reopening of the Houston Ship Channel restores an important logistics route for construction chemicals just as the U.S. enters its peak residential building season. Discover what this means for supply planning.
Pharmaceutical Supply Chain: H1 2026 Closing Risk Assessment
The first half of 2026 exposed major vulnerabilities in pharmaceutical supply chains. API concentration, shipping disruptions, and logistics risks are reshaping procurement strategies for H2 2026 and beyond.
Chemical Procurement Risks After Gulf Ship Attacks: What Buyers Need to Know in 2026
Chemical procurement teams are facing a new supply chain challenge as Gulf shipping risks increase while energy and commodity flows recover. This analysis explains how recent ship attacks could influence chemical sourcing, freight planning and supplier strategies.
GLP-1 API Supply Chain Crisis: CDMO Capacity and Peptide Sourcing Under Unprecedented Strain
The explosive success of GLP-1 therapies has created one of the most significant pharmaceutical supply chain challenges in modern history. API manufacturers, peptide synthesis facilities and CDMOs are struggling to keep pace as demand for semaglutide and tirzepatide continues to surge globally.
Don't miss out on our updates! Subscribe to our newsletter now
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.